IDO and tolerance to tumors
Tumors create a pathological state of tolerance towards tumor-associated antigens. The mechanisms by which this occurs are still largely unknown. Recent studies suggest that one mechanism contributing to this phenomenon could be tryptophan catabolism carried out by the immunoregulatory enzyme indole...
Gespeichert in:
| Veröffentlicht in: | Trends in molecular medicine 2004-01, Vol.10 (1), p.15-18 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 18 |
|---|---|
| container_issue | 1 |
| container_start_page | 15 |
| container_title | Trends in molecular medicine |
| container_volume | 10 |
| creator | Munn, David H Mellor, Andrew L |
| description | Tumors create a pathological state of tolerance towards tumor-associated antigens. The mechanisms by which this occurs are still largely unknown. Recent studies suggest that one mechanism contributing to this phenomenon could be tryptophan catabolism carried out by the immunoregulatory enzyme indoleamine 2, 3-dioxygenase (IDO). IDO can be expressed by tumor cells themselves, and we propose that the recruitment of antigen-presenting cells expressing IDO to tumor-draining lymph nodes might constitute another potent mechanism for inducing tolerance to tumor-derived antigens. Therapeutic strategies based on blocking this pathway might represent a novel class of adjuvants for tumor immunotherapy. |
| doi_str_mv | 10.1016/j.molmed.2003.11.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80098240</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80098240</sourcerecordid><originalsourceid>FETCH-LOGICAL-c334t-6301cd15e795c3442195d8d5c28de1e451d4f06d1fcb2dd14d0073c5b4cbddf23</originalsourceid><addsrcrecordid>eNqFkDtPwzAUhT2AaCn8AhDKxJZwrx-JM6LyqlSpC8xW4utIjfIodjLw70mViJXpHOk8ho-xe4QEAdOnOmn7pnWUcACRICaTXLA1ygxjmaNcsesQagBUWaav2GoKOCiNa3a3ezlERUfR0DfOF511k4uGse19uGGXVdEEd7vohn29vX5uP-L94X23fd7HVgg5xKkAtITKZbmyQkqOuSJNynJNDp1USLKClLCyJSdCSQCZsKqUtiSquNiwx_n35Pvv0YXBtMdgXdMUnevHYDRArrmEf4uYc5FpVFNRzkXr-xC8q8zJH9vC_xgEcyZmajMTM2diBtFMMs0elv-xPGd_owWX-AUwemjs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19237815</pqid></control><display><type>article</type><title>IDO and tolerance to tumors</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Munn, David H ; Mellor, Andrew L</creator><creatorcontrib>Munn, David H ; Mellor, Andrew L</creatorcontrib><description>Tumors create a pathological state of tolerance towards tumor-associated antigens. The mechanisms by which this occurs are still largely unknown. Recent studies suggest that one mechanism contributing to this phenomenon could be tryptophan catabolism carried out by the immunoregulatory enzyme indoleamine 2, 3-dioxygenase (IDO). IDO can be expressed by tumor cells themselves, and we propose that the recruitment of antigen-presenting cells expressing IDO to tumor-draining lymph nodes might constitute another potent mechanism for inducing tolerance to tumor-derived antigens. Therapeutic strategies based on blocking this pathway might represent a novel class of adjuvants for tumor immunotherapy.</description><identifier>ISSN: 1471-4914</identifier><identifier>DOI: 10.1016/j.molmed.2003.11.003</identifier><identifier>PMID: 14720581</identifier><language>eng</language><publisher>England</publisher><subject>Cell Line, Tumor ; Humans ; Immune Tolerance ; Indoleamine-Pyrrole 2,3,-Dioxygenase ; Neoplasms - enzymology ; Neoplasms - immunology ; Neoplasms - pathology ; Tryptophan Oxygenase - metabolism</subject><ispartof>Trends in molecular medicine, 2004-01, Vol.10 (1), p.15-18</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c334t-6301cd15e795c3442195d8d5c28de1e451d4f06d1fcb2dd14d0073c5b4cbddf23</citedby><cites>FETCH-LOGICAL-c334t-6301cd15e795c3442195d8d5c28de1e451d4f06d1fcb2dd14d0073c5b4cbddf23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14720581$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Munn, David H</creatorcontrib><creatorcontrib>Mellor, Andrew L</creatorcontrib><title>IDO and tolerance to tumors</title><title>Trends in molecular medicine</title><addtitle>Trends Mol Med</addtitle><description>Tumors create a pathological state of tolerance towards tumor-associated antigens. The mechanisms by which this occurs are still largely unknown. Recent studies suggest that one mechanism contributing to this phenomenon could be tryptophan catabolism carried out by the immunoregulatory enzyme indoleamine 2, 3-dioxygenase (IDO). IDO can be expressed by tumor cells themselves, and we propose that the recruitment of antigen-presenting cells expressing IDO to tumor-draining lymph nodes might constitute another potent mechanism for inducing tolerance to tumor-derived antigens. Therapeutic strategies based on blocking this pathway might represent a novel class of adjuvants for tumor immunotherapy.</description><subject>Cell Line, Tumor</subject><subject>Humans</subject><subject>Immune Tolerance</subject><subject>Indoleamine-Pyrrole 2,3,-Dioxygenase</subject><subject>Neoplasms - enzymology</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - pathology</subject><subject>Tryptophan Oxygenase - metabolism</subject><issn>1471-4914</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkDtPwzAUhT2AaCn8AhDKxJZwrx-JM6LyqlSpC8xW4utIjfIodjLw70mViJXpHOk8ho-xe4QEAdOnOmn7pnWUcACRICaTXLA1ygxjmaNcsesQagBUWaav2GoKOCiNa3a3ezlERUfR0DfOF511k4uGse19uGGXVdEEd7vohn29vX5uP-L94X23fd7HVgg5xKkAtITKZbmyQkqOuSJNynJNDp1USLKClLCyJSdCSQCZsKqUtiSquNiwx_n35Pvv0YXBtMdgXdMUnevHYDRArrmEf4uYc5FpVFNRzkXr-xC8q8zJH9vC_xgEcyZmajMTM2diBtFMMs0elv-xPGd_owWX-AUwemjs</recordid><startdate>200401</startdate><enddate>200401</enddate><creator>Munn, David H</creator><creator>Mellor, Andrew L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200401</creationdate><title>IDO and tolerance to tumors</title><author>Munn, David H ; Mellor, Andrew L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c334t-6301cd15e795c3442195d8d5c28de1e451d4f06d1fcb2dd14d0073c5b4cbddf23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Cell Line, Tumor</topic><topic>Humans</topic><topic>Immune Tolerance</topic><topic>Indoleamine-Pyrrole 2,3,-Dioxygenase</topic><topic>Neoplasms - enzymology</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - pathology</topic><topic>Tryptophan Oxygenase - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Munn, David H</creatorcontrib><creatorcontrib>Mellor, Andrew L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Trends in molecular medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Munn, David H</au><au>Mellor, Andrew L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IDO and tolerance to tumors</atitle><jtitle>Trends in molecular medicine</jtitle><addtitle>Trends Mol Med</addtitle><date>2004-01</date><risdate>2004</risdate><volume>10</volume><issue>1</issue><spage>15</spage><epage>18</epage><pages>15-18</pages><issn>1471-4914</issn><abstract>Tumors create a pathological state of tolerance towards tumor-associated antigens. The mechanisms by which this occurs are still largely unknown. Recent studies suggest that one mechanism contributing to this phenomenon could be tryptophan catabolism carried out by the immunoregulatory enzyme indoleamine 2, 3-dioxygenase (IDO). IDO can be expressed by tumor cells themselves, and we propose that the recruitment of antigen-presenting cells expressing IDO to tumor-draining lymph nodes might constitute another potent mechanism for inducing tolerance to tumor-derived antigens. Therapeutic strategies based on blocking this pathway might represent a novel class of adjuvants for tumor immunotherapy.</abstract><cop>England</cop><pmid>14720581</pmid><doi>10.1016/j.molmed.2003.11.003</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-4914 |
| ispartof | Trends in molecular medicine, 2004-01, Vol.10 (1), p.15-18 |
| issn | 1471-4914 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80098240 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Cell Line, Tumor Humans Immune Tolerance Indoleamine-Pyrrole 2,3,-Dioxygenase Neoplasms - enzymology Neoplasms - immunology Neoplasms - pathology Tryptophan Oxygenase - metabolism |
| title | IDO and tolerance to tumors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T23%3A45%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IDO%20and%20tolerance%20to%20tumors&rft.jtitle=Trends%20in%20molecular%20medicine&rft.au=Munn,%20David%20H&rft.date=2004-01&rft.volume=10&rft.issue=1&rft.spage=15&rft.epage=18&rft.pages=15-18&rft.issn=1471-4914&rft_id=info:doi/10.1016/j.molmed.2003.11.003&rft_dat=%3Cproquest_cross%3E80098240%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19237815&rft_id=info:pmid/14720581&rfr_iscdi=true |